Drug Development Pipeline
Glutathione is an antioxidant that is important to the normal functioning of the intestine and lungs. Glutathione levels have been shown to be lower in people with CF. Oral glutathione may improve growth and decrease gut inflammation in children with CF.
A phase 2 study to test the safety and effectiveness of oral glutathione in children with CF has been completed. Study results showed that glutathione was not associated with improved body mass index (BMI) in children with CF. No further development in CF is planned.
This program is funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Glutathione Studies
Completed with Results
Phase 2 study of oral glutathione in children with cystic fibrosis (GROW-IP-16)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More